1,683 Shares in Insulet Co. (NASDAQ:PODD) Bought by GF Fund Management CO. LTD.

GF Fund Management CO. LTD. purchased a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,683 shares of the medical instruments supplier's stock, valued at approximately $439,000.

A number of other institutional investors have also recently made changes to their positions in PODD. Nisa Investment Advisors LLC boosted its holdings in shares of Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier's stock valued at $1,146,000 after acquiring an additional 43 shares during the last quarter. RFG Advisory LLC purchased a new stake in shares of Insulet during the 4th quarter valued at about $247,000. CX Institutional purchased a new stake in shares of Insulet during the 4th quarter valued at about $238,000. Fifth Third Bancorp boosted its holdings in shares of Insulet by 1.4% during the 4th quarter. Fifth Third Bancorp now owns 8,560 shares of the medical instruments supplier's stock valued at $2,235,000 after acquiring an additional 116 shares during the last quarter. Finally, Juncture Wealth Strategies LLC purchased a new stake in shares of Insulet during the 4th quarter valued at about $229,000.

Insider Buying and Selling at Insulet

In other Insulet news, SVP John W. Kapples sold 5,278 shares of the stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. This represents a 18.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company's stock, valued at $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PODD. Raymond James raised their price target on shares of Insulet from $328.00 to $360.00 and gave the company an "outperform" rating in a report on Tuesday. Stifel Nicolaus boosted their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research report on Friday, February 21st. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a report on Thursday, May 22nd. Citigroup reiterated a "buy" rating and issued a $380.00 price target (up from $320.00) on shares of Insulet in a research report on Thursday, May 22nd. Finally, Oppenheimer lifted their price target on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $309.88.

Insulet Stock Performance

NASDAQ PODD traded down $3.09 on Wednesday, reaching $323.55. 919,836 shares of the stock were exchanged, compared to its average volume of 710,674. Insulet Co. has a one year low of $171.61 and a one year high of $333.24. The firm has a market capitalization of $22.77 billion, a PE ratio of 55.88, a PEG ratio of 3.62 and a beta of 1.26. The company's 50-day simple moving average is $273.47 and its two-hundred day simple moving average is $270.65. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.73 earnings per share. Analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.